|By PR Newswire||
|March 28, 2014 02:30 PM EDT||
TAMPA, Fla., March 28, 2014 /PRNewswire-USNewswire/ -- Top officials from the US FDA will meet with ISPE Members and other pharmaceutical industry leaders to discuss compliance trends and identify practical solutions for modern quality systems, technology transfer, metrics implementation and other relevant topics during the third annual ISPE-FDA CGMP Conference, taking place 2 – 4 June in Baltimore, Md. USA. The conference will explore industry hot topics in an ongoing conversation between ISPE Members and FDA to advance contemporary methods of ensuring a reliable supply of medicines. During the event, ISPE will also report on its Drug Shortages initiative.
"This annual ISPE-FDA event is well positioned to address recent comments by FDA Commissioner Margaret Hamburg around the criticality of maintaining a reliable drug supply and harmonization of global regulatory perspectives which are priorities for regulators and industry alike," said Nancy Berg, ISPE President and CEO. "The ISPE-FDA CGMP Conference is the ideal setting for addressing critical issues related to product quality and manufacturing readiness, with an agenda developed jointly by FDA and ISPE that emphasizes focused, productive and solution-driven dialogue designed to move the industry forward."
Dr. Janet Woodcock, Director, CDER, FDA, will be one of the plenary speakers for the event. Dr. Woodcock's remarks at the inaugural CGMP Conference in 2012 set the tone for much of the regulatory-industry collaboration that has occurred since the inception of this signature event. It is expected that her statements at this year's event will include an update on the FDA's Office of Pharmaceutical Quality and implementing and measuring a culture of quality. Pfizer VP, Global Quality Operations Mary Oates, PhD and AstraZeneca Executive Vice President David Smith will also present at the plenary session.
Conference content has been developed by a program committee comprised of senior leaders from both FDA and ISPE, including:
- Mike Arnold, Senior Director, Strategic Partnerships, Pfizer Global Clinical Supplies, USA
- Paul D'Eramo, Vice President, Pharmaceutical Regulatory Compliance, Johnson & Johnson, USA
- David Doleski, Director, Division of DGMPA, FDA
- Joe Famulare, Vice President, Global Compliance, Genentech Inc., USA
- Rick Friedman, Associate Director, Office of Manufacturing & Product Quality, FDA
- Brian Hasselbalch, Consumer Safety Officer, CDER, FDA
- Charles Hoiberg, Executive Director, Pfizer Inc., USA
- Tim Howard, Vice President, Global Operations, Commissioning Agents, Inc., USA
- Steve Lynn, Director, Office of Manufacturing and Product Quality, FDA
- George Millili, Senior Principal Technical Advisor, Genentech Inc., USA
- Mike Smedley, Deputy Director, Office of Compliance, FDA
Sessions, case studies and workshops will focus on new and emerging trends in compliance; development, pre-approval and technology transfer; end-to-end process control; metrics implementation; combination products; breakthrough therapies; and practical solutions to drug shortages.
Complete details of the event, including program and registration information, are available at www.ISPE.org/2014-CGMP-Conference. To obtain media credentials to cover the event, please contact ISPE Manager, Marketing Communications Danielle Hould at [email protected].
ISPE, the International Society for Pharmaceutical Engineering, is the world's largest not-for-profit association serving its Members through leading scientific, technical and regulatory advancement throughout the pharmaceutical lifecycle. The 20,000 Members of ISPE are building solutions in the development and manufacture of safe and effective pharmaceutical and biologic medicines and medical delivery devices in more than 90 countries around the world. Founded in 1980, ISPE has its worldwide headquarters in Tampa, Florida, USA. Visit www.ISPE.org for more information.
With so much going on in this space you could be forgiven for thinking you were always working with yesterday’s technologies. So much change, so quickly. What do you do if you have to build a solution from the ground up that is expected to live in the field for at least 5-10 years? This is the challenge we faced when we looked to refresh our existing 10-year-old custom hardware stack to measure the fullness of trash cans and compactors.
Aug. 26, 2016 01:30 AM EDT Reads: 1,654
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
Aug. 26, 2016 01:15 AM EDT Reads: 2,000
Aug. 26, 2016 01:00 AM EDT Reads: 1,930
Aug. 26, 2016 12:45 AM EDT Reads: 2,227
Aug. 26, 2016 12:30 AM EDT Reads: 2,886
Aug. 25, 2016 11:45 PM EDT Reads: 2,263
Aug. 25, 2016 10:45 PM EDT Reads: 1,861
Aug. 25, 2016 10:15 PM EDT Reads: 1,707
Aug. 25, 2016 09:15 PM EDT Reads: 2,191
Aug. 25, 2016 09:00 PM EDT Reads: 1,693
Aug. 25, 2016 08:45 PM EDT Reads: 1,373
Aug. 25, 2016 06:30 PM EDT Reads: 1,924
Aug. 25, 2016 05:15 PM EDT Reads: 669
Aug. 25, 2016 04:15 PM EDT Reads: 458
Aug. 25, 2016 03:30 PM EDT Reads: 1,492